Immunocytochemical analyses revealed the presence and distribution of apolipoprotein E (apo E) in normal human brain tissue as well as in 77 human intracranial neoplasms. In normal brain tissues, the perikarya of astrocytes exhibited a strong positive reaction, whereas the Bergmann glia were stained to a moderate degree. However, no immunoreactivity was observed with neurons, oligodendrocytes, ependymal cells, and choroidal epithelium. Among the intracranial neoplasms, oligodendroglioma, choroid plexus papilloma, hemangioblastoma, primary malignant lymphoma, neurinoma, meninoma, pituitary adenoma, and craniopharyngioma were all negative. Immunoreactivity in the peripheral neuroblastoma was nil. However, the perikarya of astrocytomas and glioblastomas showed a positive reaction. Analyses on the degree ofanaplasia and the amount of apo-E as an intensity of immunostaining showed a negative correlation. The astrocytic elements were stained in mixed oligoastrocytomas and medulloblastomas with glial differentiation. A few cases of ependymomas showed weak perikaryal immunostaining. Western blot analyses with anti-apo E antibody of a freshly prepared surgical specimen with astrocytomas revealed a single band with a molecular weight of -37,000. The well differentiated cultured human astrocytoma cells secreted apo E into the medium. These lines of evidence suggest that apo E may serve as a potential marker specific for astrocytomas and glioblastomas, as well as an indicator of astrocytic tumor cell differentiation. The apo E localization in human brain tumors could be clinically relevant and diagnostically useful.
Introduction
Apo E is a 34,000 D lipophilic protein of known sequence (1) , circulating in plasma as a constituent of lipoproteins such as chylomicrons, VLDL, and HDL. In the plasma it plays a key role in determining the uptake of these same lipoproteins by tissues (2, 3) . The recognition of apo E is mediated by two different receptor systems; one is the apo B, E receptor present on both hepatic and extrahepatic cells (2, 4) , and the other is the apo E receptor in the liver (5, 6) . It is generally accepted that apo E is mainly synthesized by the liver (7) . However, other tissues such as human kidney and adrenal glands also synthesize the protein (8) . A recent report by Elshourbagy et al.
extended this notion. They found apo E mRNA to be abundant in the liver, and they also detected it in many other tissues in relatively high concentrations (9) . Among these tissues was the brain.
Two lines of evidence suggested the potential importance of apo E in the central nervous system. In the cerebrospinal fluid of normal humans, apo E is present at a higher concentration (3-5% of plasma concentration) than would be expected for a filtered plasma protein (10). Furthermore, apo E mRNA is also abundant in the human brain (9) . As a first step in elucidating the underlying mechanism and implications of this finding, Boyles et al. obtained evidence for the presence of abundant amounts of apo E within astrocytes of the rat brain, by using immunocytochemical techniques (1 1). The finding that apo E is synthesized by a human neurofibrosarcoma-derived cell culture but not by benign neurofibromas has also been reported (12). These findings suggested to us the potential value of apo E, together with the general morphology of neoplastic cells, for the identification and staging of glial neoplasms of the central nervous system. In this report, we have examined the immunocytochemical distribution of apo E in both the normal human brain and the primary human brain tumors. We found that in the normal human brain, astrocytes have abundant immunoreactivity for apo E. Among brain tumors, all kinds of astrocytomas and glioblastomas exhibited an immunoreaction for apo E. A negative correlation was observed between the intensity of immunoreactivity and the degree of anaplasia. In addition, in vitro experiments using cultured astrocytoma cells demonstrated the secretion ofapo E by these cells, and a negative correlation between the secretion of apo E and the degree of dedifferentiation of these neoplastic cells. Thus, apo E may potentially serve as a specific marker for astrocytomas and glioblastomas, as well as an indicator of astrocytic tumor cell differentiation.
Methods
Preparation of affinitkpurified apo E specific IgG. Human apo E was isolated from pooled serum from normolipidemic volunteers by conventional methods (13) (14) (15) . The purity of the apo E was evaluated by isoelectric focusing and SDS-PAGE. Two New Zealand White rabbits (2.0-2.5 kg) were immunized with 0.5 mg of purified apo E, as described (16, 17) . Upon double immunodiffusion analysis, the antiserum formed a single precipitin line with apo E, whereas no reaction was observed with other apolipoproteins or with HSA.
Purified apo E (10 mg) was coupled to 5 ml of CNBr-activated Sepharose 4B gel, as described (18) . 90 ml of anti-apo E serum was applied to a column ofapo E Sepharose 4B (1.0 X 7.0 cm) equilibrated with 0.1 M borate, 1.0 M NaCl, and 0.1% Tween 20 (pH 8.0). After the column was washed extensively with the same buffer, it was eluted with 0.2 M glycine-HCl buffer (pH 2.2). The effluent fractions were rapidly neutralized to pH 7.4 and concentrated to 3.0 mg/ml. Thus, affinity-purified apo E-specific IgG (monospecific anti-human apo E antibody) was obtained.
Preparation of Fab'-horseradish peroxidase (HRP)' conjugates. Fab' antibody to apo E was conjugated with HRP (type 4, RZ = 3.0, Sigma Chemical Co., St. Louis, MO) by the maleimide method, as described (19, 20) . In brief, the F(ab32 fragment was prepared from the IgG by digestion with pepsin (Sigma Chemical Co.) at pH 3.9 for 8 h at 370C, which was followed by 40% ammonium sulfate fractionation and by Sephadex G-150 column chromatography. To prepare the Fab' fragment, 500 Ml of 2 mg/ml of F(ab')2 fragment was reduced with 10 mM 2-mercaptoethylamine (Sigma Chemical Co.) in 0.1 M sodium phosphate buffer at pH 6.0 for 90 min at 370C. The reactant was applied to a Sephadex G-25 column to remove the remaining 2-mercaptoethylamine. On the other hand, 6 mg of HRP in 1.0 ml of 0.1 M sodium phosphate buffer, pH 7.0, was incubated with 2.4 mg ofN-hydrosuccinimide of N-(4-carboxycyclohexylmethyl) maleimide (Zieben Chemicals, Tokyo, Japan) in 100 Ml ofN-N'-dimethylformamide for 20 min at 30'C. After centrifugation, the supernatant was applied to a Sephadex G-25 column equilibrated with 0.1 M sodium phosphate buffer at pH 6.0. Next, HRP and Fab' fragments thus obtained were mixed on an equimolar basis (20-80 AM) and incubated for 1 h at 37°C or overnight at 4°C, after which they were applied to an Ultrogel AcA 44 column (LKB Instrument Co., Villeneuve-La-Garenne, France) chromatography with 0.1 M sodium phosphate buffer at pH 6.5. Fractions containing monomeric conjugates composed of equimolar amounts of HRP and Fab' were used for the procedures.
The ELISA procedure. Monospecific anti-apo E antibody (affinity-purified apo E-specific IgG) prepared as above was absorbed to the well of polystyrene microtiter plates (Falcon 391 1, Micro Test I I I flexible assay plate). Each well containing I Mg of IgG in 0.1 ml of 0.1 M sodium carbonate buffer (pH 8.3) was incubated at 4°C for 16 h in a humid chamber, and the unabsorbed IgG solution was aspirated from the wells. After each well was washed three times with 0.5 ml of0.15 M NaCI (pH 7.4) (buffer A), each one was incubated for 2 h at 370C with 300 Ml of 1% BSA (fraction 5; Nakarai, Kyoto, Japan) in 10 mM sodium phosphate buffer (pH 7.4) containing 0.15 M NaCl to avoid nonspecific binding of the proteins to the wells. The wells were then washed with 0.5 ml of 0.15 M NaCl (pH 7.4) and incubated overnight at 4°C with 100 Ml of samples. After aspiration of the sample solution and washing in the same manner as described above, 100 M1 of peroxidase-labeled Fab' (1 Mg/ml) was added to each well. Incubation was carried out for 2 h at 370C and the wells were aspirated and washed four times, in the same manner. The enzymatic color reaction was developed, using (2,2'Azino-bis [3-ethyl- Immunocytochemical study. A sample of human brain tissue of a 34-yr-old male was used as a normal control. He had been autopsied 6 h after death due to pneumonia. Consent for the sample collection was obtained from his family. Human brain tumors were obtained at the time of surgical procedures and were fixed in 10% formaldehyde solution for 2 d, embedded in paraffin, and sectioned into a width of [4] [5] Mm. Freshly prepared sections were deparaffinized and placed in a blocking solution of 3% H202 for 30 min and then in another blocking solution of normal goat serum for 30 min, followed by incubation overnight at 40C with primary antibodies, diluted in 3% BSA in PBS. The primary antibodies were rabbit affinity-purified apo E-specific IgG at 1:3,000, rabbit IgG against glial fibrillary acidic protein (GFAP) (DAKO, Santa Barbara, CA) at 1:2,000, or nonimmune sera at 1:500.
The slides were washed extensively with PBS and then incubated in a second antibody (affinity-purified biotinylated goat anti-rabbit IgG) for 40 min at room temperature according to the recommended dilution. Then they were washed extensively and incubated for 30 min in an avidin-biotin complex (ABC Kit; Vector Laboratories, Inc., Burlingame, CA) at room temperature. To detect the presence of peroxidase, the sections were incubated for 5-10 min at room temperature with 0.2 mg/ml ofdiaminobenzidine in 50 mM Tris-HCl buffer (pH 7.2) in the presence of 0.01 M H202, and then washed. Nuclei were counterstained with hematoxylin. Interference was never observed even when using normal goat serum as a blocking solution. To establish specificity of the immunocytochemical reaction, each reagent used was omitted in turn. Controls using nonimmune rabbit sera showed a negative staining.
Human glioma culture. Two types of human glioma cells used in these experiments were prepared in the following manner; freshly resected astrocytoma (Gr-2) or glioblastoma tissues obtained during surgical procedures were minced into a fine pulp and placed in 0.25% trypsin/0.02% EDTA solution for 30 min with mixing at 37°C in 5% CO2 incubator. The cells were centrifuged at 120 g for 3 min, and the pellets were resuspended in fresh medium and used for culture in RPMI 1640 medium (Nissui Pharmaceutical Co., Tokyo) containing 10% FCS (Biocell Laboratories, MD). Thus, the primary culture of astrocytoma served for the experiments. The glioblastoma cell line (KMG-5) that was used was established in our laboratory (22) . The glioma cells were plated to 24-well (16 X 16 mm) polystyrene dishes. Each well had 1.0 X 105 cells in I ml of culture medium. After the medium was preincubated in the absence or presence of 10 Mgg/ml ,B-methasone, dibutyryl-cAMP (db-cAMP) (1 mM) (Sigma Chemical Co.) or 100 Mig/ml LDL, which was isolated by sequential ultracentrifugation of human plasma (d, 1.019-1.063) for 24 h, it was replaced. The amounts of apo E secreted into the culture medium were determined over 72 h using ELISA.
Results
Identification and characterization of apo E in astrocytoma tissues. To examine the property of apo E found in human astrocytoma obtained at the time of surgical procedures, tumor tissue was extracted and analyzed by gel electrophoresis, followed by immunoblot, as described in Methods. Using a monospecific anti-apo E antibody, an immunoblot of tissue extracts of low grade astrocytoma revealed a single band with a molecular weight of -37,000 D, an apparently higher molecular mass than that of human plasma apo E (Fig. 1) .
Immunocytochemical demonstration of apo E in normal human brain. The sections of formaldehyde-fixed normal human brain were examined by light microscopy for the presence of immunoreactive apo E. In all of the major subdivisions, such as cerebrum, cerebellum, pons, medulla, and spinal cord, astrocytes were intensely immunoreactive for apo E from both surgical and autopsy specimens (Fig. 2 identified by conventional morphology and GFAP immunoreactivity. Immunoreactive apo E was predominant around the nucleus of most astrocytes, although some of their processes were stained for apo E. Astrocytic processes that end on basement membranes along the blood vessels were visualized by the reaction product for apo E. The reaction product for apo E was almost of equal intensity for both protoplasmic astrocytes of the gray matter and fibrous astrocytes of the white matter (data not shown). Small blood vessels were not reactive for apo E (Fig. 2) , although some large blood vessels were lined by the reaction product for apo E (data not shown). Neither neurons nor satellite oligodendrocytes were reactive for apo E (Fig. 2) . Bergmann glia (Fig. 3 ) and pituicytes (Fig. 4 GFAP, reactive cell processes of the Bergmann glia that transversed the molecular layer and lined the surface ofthe cerebellum were absent (Fig. 3) . Neither ependymal cells nor choroidal epithelium were reactive for apo E. Parallel experiments revealed that GFAP is found in the perikarya and processes of astrocytes, Bergmann glia and pituicytes, but not in other nervous tissues. This was identical with data in the literature (Table I) (23, 25, 26).
Immunocytochemical demonstration of apo E in human brain tumors. On examination of 18 subtypes ofastrocytomas, all showed perikaryal immunoreaction for apo E. In pilocytic astrocytomas, most of the cells were strongly accentuated by immunostaining. Approximately 80% of the cells among the protoplasmic (low grade) astrocytomas showed abundant staining, and the remaining ones showed a weak but significant immunoreaction (Fig. 5) . Parallel experiments in the same fields revealed abundant immunoreactivity for GFAP in the perikarya and processes of most neoplastic astrocytes in low grade astrocytomas. This also was identical with data in the literature (23, 27). On examination of anaplastic (high grade) astrocytomas, a moderate degree of immunoreaction for apo E was observed in only a few cells, while a large number ofthe cells was intensely stained for GFAP. No immunoreaction for apo E was observed in some areas where a strong immunoreaction for GFAP was seen (Fig. 6 ). Correlations between tumor grading and apo E or GFAP immunoreactivity in 18 astrocytomas are summarized in Table II . The negative correlation was greater in the case of apo E immunoreactivity than in GFAP. All cases of nine glioblastomas examined also showed perikaryal immunoreaction for apo E. Varying apo E immunoreactivities were seen as follows. In one case (case 1) (Fig. 7) , cells with a gemistocytic or bizarre form were moderately to intensely stained. The cells oflarge and multinucleated forms were weakly stained. Small, round components showed little or no staining. The area of necrosis remained unstained.
In parallel experiments, a higher GFAP immunoreactivity was detected, especially in the perivascular areas, in comparison with apo E contents. Another case (case 2) (Fig. 7) likewise showed that only a few neoplastic cells showed a weak immunoreaction for apo E, whereas a large number of the cells revealed GFAP immunoreaction to a moderate degree, especially in the perivascular areas. Some reactive astrocytes admixed with neoplastic cells were intensely stained (data not shown).
To determine whether the apo E reactive cells were neoplastic ones or invaded macrophages, human macrophage-specific antibody (28) was used for cell identification in case 2 of glioblastoma. This case was chosen for study because some of the apo E-reactive cells seemed to have a foamy appearance and the small dark nuclei typical of macrophages. None of the cells were stained positively (Fig. 7) .
On examination of 10 ependymomas, only two showed apo E immunoreactive material, and here, -10% of the cells showed weak perikaryal staining for apo E. In contrast, all exhibited strong perikaryal immunoreaction for GFAP. In seven, > 70% of the cells revealed strong GFAP immunoreactivity, and in the remaining three, 10-20% of the cells showed strong immunoreaction for GFAP (Fig. 8) .
On examination of three oligodendrogliomas, no apo E positive tumor cells were evident, whereas GFAP positive tumor cells, which amounted to -40% of the tumor cells, were present in all three cases (Fig. 9) . In cases of mixed oli- On examination of 12 medulloblastomas, only three exhibited immunoreactivity for apo E. In one, the surgical specimen revealed a highly cellular tumor composed of small, round to polygonal cells with hematoxyphilic nuclei and no special arrangement. No distinct processes were recognized in these cells. Mitotic figures were frequently observed. Strong positive staining for apo E was observed in a few of these cells, which formed small clusters. The perikarya and polar processes as well were intensely stained for apo E. In parallel experiments, the case described above exhibited a strong positive reaction for GFAP in the perikarya of the cells, and in serial sections simultaneously exhibited apo E immunoreaction in the same fields (Fig. 10) . The difference of immunostaining patterns between apo E and GFAP is unknown. In another two apo E positive cases, one of which demonstrated the coexistence of apo E and GFAP, abundant immunoreactive materials were Figure 4 . Apo E localization in human pituitary gland (dark reaction product) (X 300). Fine and thin staining is seen in the perikarya of the pituicytes (arrowheads). Light counterstain with hematoxylin was used. Figure 3 . Apo E localization in human cerebellum (dark reaction product) (X 800). Giant unreactive Purkinje cells for apo E (P) are surrounded by smaller Bergmann glia, the perikarya of which is rective for apo E (arrowheads). The processes of Bergmann glia are not rich in immunoreactive apo E. Light counterstain with hematoxylin was used.
observed in the perikarya of only a few neoplastic cells. Morphologically, the positive cells were neoplastic cells, not reactive astrocytes, and were similar in shape and size to the coexisting unstained cells.
No immunoreaction for apo E was seen in other intracranial neoplasms such as choroid plexus papillomas, hemangioblastomas, primary malignant lymphomas, neurinomas, meningiomas, pituitary adenomas, and craniopharyngiomas (Table III) . Peripheral neuroblastomas also showed no immunoreaction for apo E (Fig. 1 1) . In parallel experiments using paraformaldehyde-fixed frozen sections of the human normal brain or of brain tumors, immunocytochemical demonstration revealed evidence identical with that obtained in the paraffin-embedded sections. That is, a weakly positive immunoreaction for apo E occurred in cells of anaplastic astrocytomas, and there was no immunoreaction for apo E in neurons, oligodendrogliomas, neuroblastomas, neurinomas, and meningiomas, even when the frozen tissues were reacted with mono- , A ,j. U t3' Is4 44*~4 9, , Figure 7 . The difference between apo E and GFAP immunoreactivity in glioblastoma. In case 1 (A and B), the cells with a gemistocytic or bizarre form (arrow) are moderately to intensely reacted for apo E and the cells with large and multinucleated forms are weakly reacted for apo E, and the small, round components show very little or no immunostaining for apo E (arrowheads). In addition, serum components within the blood vessel (V) show a strong reaction for apo E (A, X 260). In contrast, a higher GFAP immunoreactivity is detected in several varieties of the cells in the same field as A in serial sections specific anti-apo E antibody at 1:3,000. In addition, the most appropriate dilution of the monospecific anti-apo E antibody to use was 1:60,000, thereby indicating that apo E is fixation sensitive (data not shown). Secretion of apo E from cultured glioma cells. To investigate whether apo E was secreted from the astrocytic tumor cells into the cultured medium, the following study was performed (Fig. 12) . Upon primary culture of the low grade astrocytoma, a significant amount of apo E was detected at the basal value in medium. The secretion of apo E from the cells was enhanced 1.8-2.0-fold by fl-methasone, db-cAMP, or LDL. The mechanism is unknown. In contrast, no apo E secretion was observed with the glioblastoma cell line (KMG-5), even in the presence of various agents. In addition, the immunofluorescence study using cultured cells indicated that the primary culture of the astrocytoma contained -80% GFAP positive cells and the cell line contained -5% or less (data not shown). To examine whether apo E detected in the medium is due to tumor cell destruction, we measured lactate dehydrogenase activity of the culture medium. The lack of lactate dehy- drogenase activity in the medium indicates that the astrocytic tumor cells remained intact during the experimental period (data not shown).
Discussion
We obtained evidence that all types of astrocytomas and glioblastomas exhibit an immunoreaction for apo E, with a negative correlation between the intensity ofimmunoreactivity and the degree of anaplasia. The astrocytic elements are stained in the case of the medulloblastoma with glial differentiation. In addition, well differentiated cultured astrocytoma cells secrete i:++6s k & of~i'O4 a n d apo E. Thus, the possibility that apo E can serve as a marker of astrocytic tumors as well as an indicator of astroglial cell differentiation warrants attention. Although the function of apo E in lipid metabolism and its relation to atherosclerosis is fairly well understood (3), the discovery that apo E is present in the normal nervous tissue is a recent one (9-1 1), hence little is known of its role in the nervous system. The findings to date in the nervous system are summarized.
Apo E expression in normal state. In the rat brain, Boyles et al. showed that astrocytes and certain nonmyelinating Schwann cells in vivo synthesize apo E but that myelinating Apo E expression in nerve injury. After peripheral nerve injury, apo E was found to be significantly increased in the degenerating portion of the nerve (29) (30) (31) (32) (33) . Invading macrophages are the major source of this protein (33) . After central nerve injury, apo E was found to increase in the brain tissue (32) . However, macrophages apparently did not play the dominant role at the onset of degenerative events, rather reactive astrocytes appeared to contribute to the total amount of the protein in the damaged nerve early in the history of the lesion, with macrophages contributing significantly only some weeks later (33) .
Apo E expression in neoplasms. Apo E was found to be synthesized by human neurofibrosarcoma-derived cell culture, but not by cells from benign neurofibroma (12). However, these cases are rare and the authors did not clearly establish that immunocytochemical localization of apo E is a useful approach for identification or staging of human glial neoplasms.
The present study focuses on the usefulness of apo E for diagnosis. Our results indicate that apo E localization in Figure 10 . Apo E and GFAP localization in medulloblastoma. Small, round to polygonal cells with highly hematoxyphilic nuclei and no special arrangement are evident. No distinct processes are recognized (A, hematoxylin-eosin staining, X 320). Strong positive staining for apo E is seen in the perikarya (arrowheads) and polar processes (arrows) as well (B, X 800). In the same fields as B in serial sections, the cells simultaneously express a strong GFAP immunoreaction in the perikarya (C, X 800). Light counterstain with hematoxylin was used. human brain tumors may be clinically relevant and diagnostically useful.
As macrophages are present in some neoplasms, and secrete copious quantities of apo E (34), the question arises as to whether apo E-reactive macrophages are present in the specimen used. To ascertain this critical point, human macrophage-specific antibody (28) was used for cell identification. The finding that none of the cells were stained positively in case 2 of glioblastoma would argue against the apo E-reactive cells being macrophages (Fig. 7) .
The apo E reactivity identified in neoplastic astrocytic cells appears to be synthesized by these cells. The possibility that apo E from the plasma enters these tumors where the bloodbrain barrier no longer exists can be ruled out. If such were true, most apo E immunoreactive cells would be expected to be found in regions closest to the blood vessels. This is not the case. Preliminary electron microscopic immunohistochemical investigations have shown that apo E is present in the Golgi apparatus of astrocytoma cells (unpublished observation). In addition, the apparently higher molecular mass of apo E from tissue extracts of a human glioma (-37,000 D), compared with 34,000 D for plasma apo E, would argue against the point All cases of astrocytomas and glioblastomas that were examined exhibited a positive immunoreaction for apo E. Only 2 of 10 ependymomas examined exhibited an immunoreaction for apo E. Only 3 of 12 medulloblastomas examined exhibited an immunoreaction for apo E. In contrast, all 10 ependymomas and only 2 of 12 medulloblastomas showed immunoreaction for GFAP. No immunoreaction for apo E was seen in oligodendrogliomas, choroid plexus papillomas, neuroblastomas, hemangioblastomas, primary malignant lymphomas, neurinomas, meningiomas, pituitary adenomas, and craniopharyngiomas. * 1 shows that only astrocytic components of mixed gliomas revealed an apo E immunoreaction and *2 shows that both components in one case and only astrocytic components in the other were stained for GFAP.
that apo E is of plasma origin. This apparently higher molecular weight may be due to sialylation (35) and has been reported previously for brain and neural tissue apo E (1 1, 29-33 ).
Antibodies to GFAP are apparently not species-specific (36, 37). Our anti-human apo E antibody, however, did not react with either bovine (Fig. 1) or rat serum apo E (data not shown), thereby indicating that the antigenic determinants for apo E differ between these species.
It has been established that GFAP is localized in astrocytes and in Bergmann radial glia of cerebellum, but not in other nervous tissue cells such as neurons, oligodendrocytes, ependymal cells, and choroidal epithelium (26, 38) . Furthermore, it is generally accepted that GFAP is present in glioma with a negative correlation to the degree of anaplasia, hence indicating that GFAP is a marker ofglial cell tumors (23, 27). Several investigators (39) (40) (41) (42) (43) using immunocytochemical techniques have demonstrated that in ependymal and oligodendroglial tumors a high number of GFAP-positive neoplastic elements Figure 11 . Apo E immunoreactivity in neuroblastoma (X 230) Immunoreaction for apo E is nil.
are detected and a high GFAP content can be detected even in malignant glioma as well as in low grade glioma. They seemed to favor the view that GFAP is not an astrocyte-specific but rather a glial-specific protein, and that a GFAP investigation does not always seem reliable for evaluating undifferentiated tumors.
Our results suggest that apo E can serve as a marker for astroglial cell tumors and their differentiation. This seems to be in general agreement with the results obtained by GFAP localization. The present study demonstrated that all of the cases of ependymomas and oligodendrogliomas that were examined possessed abundant amounts of GFAP, whereas a few cases among the ependymomas exhibited a weak immunoreaction for apo E, and no cases among oligodendrogliomas showed a reaction product for apo E. Second, on examination of anaplastic astrocytomas and glioblastomas, the GFAP immunoreaction is much more intense than the apo E immunoreaction. Our results, therefore, suggest that apo E, more that GFAP, is a valuable marker of astrocytic tumors as well as an indicator of cell differentiation. Naturally, a combined apo E/GFAP profile of immunoreaction would further aid in the identification and staging of glial neoplasms ofthe central nervous system. It should, therefore, prove to be a clinically useful antigenic determinant.
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